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Key Points
• T-cell receptor anti-
bodies were used to
discriminate tumor and
TILs in MF skin biopsies.
• This showed a surpris-
ingly similar phenotype
on TILs between pa-
tients, whereas tumor
phenotype clustered
into 3 groups by
HLA-DR.
Immunotherapy is a valuable treatment for many cancer patients, and there is
considerable interest in understanding the mechanisms of immune evasion to guide
appropriate management. Mycosis fungoides (MF) is a malignant disorder of skin-homing
CD41 T cells, and it exhibits a highly variable clinical course during which the tumor-speciﬁc
immune response may be an important determinant. An unusual feature of MF is that
tumor-inﬁltrating lymphocytes (TILs) must attempt to control a malignant cell from
within their own lineage. We obtained skin biopsies and blood from 43 patients with
CD41 MF and undertook a detailed phenotypic and functional analysis of CD41 and CD81
T cells. Clonotypic TCRBV staining allowed delineation of malignant and reactive CD41
subsets. CD41 and CD81 TILs displayed a comparable “exhausted” phenotype that was
characterized by expression of PD-1 and TIGIT but retained cytotoxic activity and
production of interferon-g and interleukin-17 in early-stage disease. In contrast, tumor
cells were much more heterogeneous and were divided into 3 discrete subsets based on
differential expression of HLA-DR: “cold” (DR2), “exhausted” (DR1 PD-11), and “evasive”
(DR11 PD-L11) phenotypes. Disease progression was associated with increasing
divergence of the tumor phenotype away from that of TILs and reduced functional
activity within TILs. These observations reveal that the phenotype and function of TIL
populations are constrained at all stages of disease, whereas the tumor evolves discrete
phenotypic proﬁles of escape during clinical progression. The ﬁndings should help to
direct appropriate immunotherapeutic interventions for individual patients.
Introduction
Tumor-specific immune responses play an important role in the control of malignant disease,1 and
immunotherapy is now an effective therapy for many tumor subtypes.2,3 Mycosis fungoides (MF) is a
T-cell lymphoma of the skin, generally of the CD41 lineage, and it remains incurable with current
therapy. Early-stage MF (IA-IIA) has an indolent course, although 25% of patients progress to
advanced-stage MF (IIB-IV), which has a median survival of 3 years.4 No treatment has been shown to
prolong survival, and therapy currently focuses on skin-directed therapies in early-stage disease and
systemic therapy for advanced stages of disease.
Allogeneic stem cell transplantation can sometimes establish long-term disease control and reveals
susceptibility of the tumor to a “graft-versus-leukemia” immune response. Despite this, there is little
understanding of the features or potential importance of autologous tumor-specific immune responses.
MF tumors acquire a wide range of genetic mutations,5,6 which could represent a potential source of
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neoantigens for recognition by tumor-infiltrating lymphocytes (TILs).
Indeed, a substantial immune infiltrate is often observed, and CD81
T-cell infiltration is correlated positively with disease control.7 PD-L1
expression on tumor cells is seen in some cases8,9 and may correlate
with response to checkpoint blockade,10 although the overall response
rate is relatively disappointing (;15%-38%).9,11
Analysis of the immune microenvironment within MF could help
to guide the rational introduction of immunotherapeutic manage-
ment. However, the difficulty of distinguishing between the T-cell
tumor cells and the reactive T-cell infiltrate remains a considerable
challenge. Here, we used T-cell receptor (TCR)–based identifica-
tion of the tumor population to undertake a detailed phenotypic and
functional analysis of the CD41 and CD81 TILs and contrast this
with features of the malignant cells. We demonstrate that TILs
express a homogeneous phenotype and function across all patient
groups, whereas tumor cells are markedly heterogeneous between
different patients but fall into 3 broad groups based on the relative
expression of HLA-DR. Moreover, disease progression is charac-
terized by increasing divergence of the tumor cell phenotype away
from that of TIL subpopulations. These observations should prove of
value in understanding the mechanisms of tumor evasion and for
guiding personalized immunotherapeutic interventions.
Methods
The study received ethical permission from the regional ethics
committee (West Midlands–Coventry and Warwickshire Re-
search Ethics Committee) on 8 January 2016, and all participants
gave written informed consent as per the Declaration of Helsinki.
A 6-mm punch biopsy and 20 mL of peripheral blood (PB) were
taken from patients with MF. PB was analyzed from 10 age-
matched healthy donors, and 2 patient skin biopsies were taken at
sites of uninvolved normal skin.
Patients with patch, plaque, or tumor MF were selected. The
1 patient with Se´zary syndrome had tumorous skin involvement.
The age, stage, previous treatments, and time since diagnosis were
recorded.
Generation of single-cell suspension
The biopsy was macerated with scalpels, added to 5 mL of growth
media (RPMI 1640 [Sigma-Aldrich], 10% fetal calf serum, 1%
L-glutamine, 1% penicillin-streptomycin) and 0.1% weight-to-volume
ratio (w/v) collagenase D (Sigma-Aldrich) and placed on a rotator
(Miltenyi Biotec) overnight at 37°C prior to filtration through a 70-mm
filter. PB was diluted 1:1 with wash media (RPMI 1640 [Sigma-
Aldrich], 1% penicillin-streptomycin), layered on Lymphoprep (Axis-
Shield), and centrifuged at 2000 rpm for 30 minutes without brake.
The PB mononuclear cell (PBMC) layer was extracted and washed
twice (1500 rpm, 10 minutes) with wash media (Figure 1).
Analysis of TCRBV expression on T cells within tumor
Cells were suspended in 100 mL of MACS buffer (Oxoid Phosphate
Buffered Saline, bovine serum albumin [0.5% w/v], and EDTA
[0.07%w/v]) and stained with Fc blocker (TruStain FcX; BioLegend),
followed by anti-CD3, -CD4, -CD8, -CD7, and -TCRBV region-
specific antibodies for 30 minutes. After washing, viability dye was
added (propidium iodide; Miltenyi Biotec), and cells were analyzed on
a Beckman-Coulter Gallios flow cytometer at low speed. FCS3 files
were analyzed in Kaluza (v1.5), and “clonograms” were generated
based on TCRBV-specific staining. Nonclonotypic samples had peak
TCRBV populations representing ,25% of the repertoire, whereas
clonotypic samples were defined as those representing.40% of the
repertoire.
Flow cytometric analysis of immune
checkpoint expression
Cells were stained with Fc blocker, anti-CD3 (SK7, APC-Cy7;
BioLegend), anti-CD4 (OKT4, AF700; BioLegend), anti-CD8 (RPA-T8,
BV510; BioLegend), the selected anti–TCR-Vb (phycoerythrin
[PE]/FITC; Beckman-Coulter), anti-CD14 (HCD14, PE/Dazzle 594;
BioLegend), anti-CD19 (HIB19, PE/Dazzle 594; BioLegend), anti-
CD56 (5.1H11, PE/Dazzle 594; BioLegend), anti–PD-1 (EH12.2H7,
PE-Cy7; BioLegend), anti–PD-L1 (29E,2A3, BV421; BioLegend),
anti–PD-L2 (MIH18, APC; BioLegend), anti-TIGIT (MBSA43, PerCP-
EF710; eBioscience), anti–TIM-3 (F38-2E2, BV421; BioLegend),
anti-LAG3 (11C3C65, AF647; BioLegend), anti-galectin 9 (PM1-3,
PerCP-Cy5.5; BioLegend), anti–HLA-DR (LN3, PE-Cy7; BioLegend),
anti–MHC-I (W6/32, PE-Cy7; BioLegend), anti-CD95 (DX2, BV421;
BioLegend), and anti-Fas Ligand (NOK1, APC; BD Biosciences).
Cells were stained for 30 minutes at 4°C, washed in MACS buffer,
and stained with propidium iodide prior to analysis.
Identification of regulatory T cells
Cells were washed twice with phosphate buffered saline (PBS;
Oxoid Phosphate Buffered Saline, Dulbecco A) prior to addition of
fixable viability dye and Fc receptor blocker (BioLegend). Antibodies
against CD3, CD4, CD8, CD25, and the identified “clonotypic”
TCRBV were used to stain cells prior to permeabilization (Human
FoxP3 Buffer Set; BD Biosciences) and staining with anti-FoxP3
(259D, AF647; BioLegend).
Intracellular cytokine staining
Cells were added to 1 mL of warm growth media supplemented
with 13 protein transport inhibitor cocktail (eBioscience), with
or without cell stimulation cocktail (eBioscience), and incubated at
37°C, 5% CO2 for 4 hours. Samples were agitated, washed twice
with PBS, and resuspended in 10 mL of PBS. Fixable viability dye
was added, followed by FcR block. Antibodies against CD3, CD4,
CD8, and specific TCRBV were added, and samples were
incubated in the dark for 20 minutes, washed, and resuspended.
A total of 50 mL of 4% paraformaldehyde (Sigma-Aldrich) was
added, and samples were vortexed, incubated for 15 minutes,
washed in MACS buffer, resuspended in supernatant of 1% saponin
(Sigma-Aldrich), and incubated for 10 minutes in the dark at room
temperature. Intracellular cytokine antibodies (against interferon-g
[IFN-g] B27 PerCP-Cy5.5; interleukin-4 [IL-4] MP4-25D2 PE-Cy7;
IL-10 JES3-19F1 APC, and IL-17A BL168 BV421; BioLegend) were
added to samples, which were incubated for 25 minutes in the dark
at room temperature prior to washing and analysis.
Flow cytometric analysis
FCS3-format flow cytometry data were analyzed with Kaluza
(Beckman-Coulter v1.5) using a sequential gating strategy to
identify singlets, lymphocytes, and T cells and using a Boolean
strategy to identify the 5 populations of interest: PB CD8 (CD31
CD81 PB), PB CD4 (CD31 CD41–specific Vb2 PB), TIL CD8
(CD31CD81 skin), TIL CD4 (CD31CD41–specific Vb2 skin), and
tumor (CD31 CD82–specific Vb1 skin). Specific parameters were
obtained by gating on negative populations or by measuring geometric
mean of fluorescence. The fluorescence was compensated using
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single-stained beads. Further analysis was performed in R.12
Geometric mean of fluorescence was transformed using the
inverse hyperbolic sine, and then fold change was calculated
by subtracting transformed skin expression from transformed
PBMC expression.
Results
Staining with TCRBV-specific antibody can
distinguish between tumor and TIL populations in
many cases of MF
A total of 49 skin biopsies and blood samples was obtained from
43 patients, of whom 42 had MF stage IA (n 5 7), IB (n 5 17), IIA
(n5 1), IIB (n 5 14), IIIA (n 5 1), or IVA2 (n 5 2), and 1 had Se´zary
syndrome IVA1 (n5 1) with tumor-stage skin disease. If.1 biopsy was
obtained from a patient, they were from different skin lesion types
(eg, plaque and tumor) (Table 1).
A single TCRBV-specific antibody stained between 43.1% and
97.6% of the total CD41 (n5 14) or CD4low (n5 4) T-cell repertoire
in 18 patients (43%), and these samples were deemed clonotypic
(Figure 1C). In 1 case of blood involvement, the clonotype
represented .40% of the PB CD4 population but 12% of tissue
CD41 T cells. In contrast, peak TCRBV-specific staining ranged
from 0.45% to 23.3% of cells in nonclonotypic samples. Clonotypic
cells were assumed to represent the MF tumor lymphocytes,
whereas CD41 T cells that stained with the other TCRBV-specific
antibodies were identified further as TILs. Importantly, the size and
cellular complexity (as determined by forward scatter and side
scatter, respectively, on fluorescence-activated cell sorting) were
markedly increased on the tumor population (P , .0001, Wilcoxon
rank-sum test [Wilcoxon]). CD7 expression was also downregulated
on tumor cells in 4 of 5 cases examined. MF tumors expressed a
range of TCRBV families, and no pattern of TCR conservation was
observed within the group (data not shown).
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Figure 1. Method and cell population determination. (A) Illustration of method. (B) Example of flow cytometry gating of skin and PBMC samples. (C) Plot of T-cell
constituent populations in clonotypic samples. In the penultimate 3 samples, the clonotypic population represented .40% of the CD4low (DNEG) population; in the last
sample, the clonotype was .40% of the PB CD41 cells. (D) Mean forward and side scatter of the 5 analyzed populations.
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Tumor-infiltrating CD41 and CD81 lymphocytes
express a homogeneous PD-11 TIGIT1
“exhausted” phenotype
In initial studies, we examined the membrane phenotype of CD41
and CD81 TILs and compared it with tumor and PB (PBMCs).
CD41 and CD81 TILs exhibited coexpression of a range of
exhaustion markers, and it was noteworthy that this phenotype was
broadly similar in patients at different disease stage. Notably, CD4
TILs showed strong upregulation of PD-1 (P , .0001) and TIGIT
(P , .0001) compared with PBMCs, although the levels of LAG-3
were low. TIM-3 expression was higher on TILs compared with
patient PBMCs (P , .001 and P , .01 for CD8 and CD4) but not
control PBMCs. Expression of MHC-I, MHC-II (HLA-DR), and Fas
was markedly increased on TILs (P , .001, P , .0001, and P ,
.0001), but PD-L1 and PD-L2 levels were similar to blood (Figure 2).
Analysis of T cells from skin biopsies of uninvolved areas showed
lower expression of PD-1, Fas, TIGIT, and HLA-DR compared with
TILs (data not shown). The coexpression profile of checkpoint
proteins is a more reliable marker of functional T-cell exhaustion
compared with single expression. As such, we also examined the
pattern of coexpression of PD-1 and TIGIT on CD41 and CD81
TILs, which revealed that a median of .30% of TILs expressed
PD-1 and TIGIT compared with ,10% of cells within blood
(supplemental Figure 1).
The proportion of regulatory T cells (Tregs) within TILs was
determined by assessment of the Foxp31 CD251 subpopulation.
Tregs were increased substantially compared with PBMCs, although
a wide variation was observed between different tumors (median,
17%; range, 0-34% vs 6% PBMCs; P5 .006, Wilcoxon signed-rank
test [paired Wilcoxon]). Treg populations were low within blood,
although an increase from 4% to 8% was seen with increasing
clinical stage (group IB vs IIB, P 5 .04, Wilcoxon; data not shown).
Interestingly, the phenotype of CD81 TILs was virtually identical to
that of CD41 TILs, with a PD-11 TIM-31 TIGIT1 Fas1 profile and
increased levels of HLA class I and class II. Again, TIM-3 levels were
lower on patient PBMCs compared with those from healthy donors.
This CD41 and CD81 TIL phenotype reveals that both subpopu-
lations are undergoing sustained T cell signaling and is most likely to
reflect chronic antigenic recognition of tumor.
Tumor cells display phenotypic heterogeneity and can
be separated into 3 groups based on relative
expression of HLA-DR
We next studied the phenotype of MF tumors and observed
extreme heterogeneity compared with TILs (Figure 2). Interestingly,
many tumors shared the same exhausted (PD-11 TIM-31 TIGIT1)
phenotype that had been observed on TILs, and expression of PD-1
and TIGIT was remarkably high in some tumors. Fas and CD25
expression was also highly variable. Interestingly, PD-L1 and PD-L2
expression was not increased in MF, and there was no evidence
of downregulation of MHC-I expression. HLA class II (HLA-DR)
expression was highly variable, with different tumors characterized
by absent, low, or high expression. Foxp31 expression was observed
at a median level of 2% (range, 0-17%; P, .001 vs CD4 TILs, paired
Wilcoxon), indicating that MF tumors are not primarily of a regula-
tory phenotype, although Foxp31 cells represented .10% of tumor
cells in 2 tumors (Figure 2).
Principal component analysis was used to examine the pattern of
coexpression of surface markers on tumors and TILs. This showed
that CD4 and CD8 TILs clustered together closely, whereas tumor
populations were distributed in 3 groups (Figure 3A).
K-means clustering was used to interrogate tumor subsets further and
results were displayed as a heat map of protein expression in MF
(Figure 3B). This demonstrates that the 3 groups can be separated,
based on HLA-DR expression, into a small group that lacks expression
of HLA-DR and virtually all other markers (n 5 3), a dominant
proportion of tumors that expresses HLA-DR together with PD-1 and
TIGIT (n 5 13), and a small proportion of MF with very high HLA-DR
expression associated with Fas and PD-L1 expression (n5 4). On the
basis of this profile, we chose to classify these subsets as “cold,”
“exhausted,” and “evasive” tumors, which represent 17%, 66%,
and 17% of all cases.
The TIL phenotype is comparable across all 3
tumor subtypes
To relate tumor phenotype to that of their associated TILs, we next
examined the profile of coexpression across the 3 subgroups
(Figure 3C). Importantly, the TIL profile was homogeneous across the
3 subsets and no difference in the “exhaustion” profile or proportion of
Table 1. Clinical features of patients
Feature Value
Diagnosis, n
MF 42
Se´zary syndrome* 1
Clinical characteristics
Age, median (range), y 67 (26-86)
Died 6 (14)
Erythrodermic 3 (6)
Patch-stage lesions 4 (8)
Plaque-stage lesions 21 (42)
Tumor-stage lesions 19 (38)
Normal skin 2 (4)
SCC (excluded) 1 (2)
Pathological characteristics
Large cell 14 (33)
CD8 phenotype 1 (2)
Ki67, median (range), % 31 (0-100)
Folliculotropic 21 (49)
Stage, n
IA 7
IB 17
IIA 1
IIB 14
IIIA 1
IVA1 1
IVA2 2
Unless otherwise noted, data are n (%).
SCC, squamous cell carcinoma.
*With tumors showing large cell transformation.
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Figure 2. Violin plots of populations of interest for measured parameters. This shows the general trend for upregulation of immune checkpoint receptors on the TIL
populations, as well as the heterogeneity of the tumor populations in specific markers, particularly PD-1, PD-L1, FasR, TIGIT, and HLA-DR. *P , .05; **P , .01; ***P , .001;
****P , .0001.
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Tregs was observed. Indeed, the only difference was a modest
decrease in Fas expression onCD41TILs in the setting of “cold” tumors.
T-distributed stochastic neighbor embedding (tSNE) dimension
reduction separated tumor and TIL subsets and allowed visualization
of the relative magnitude of the 2 populations and the heterogeneity of
surface expression within subpopulations. Although aggregate analy-
sis of TILs had shown consistent upregulation of immune checkpoint
inhibitory receptors, the tSNE plot did reveal some heterogeneity in
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receptor expression (Figure 3D). These findings show that the TIL
phenotype is “frozen” across all subtypes of MF tumor and is not related
to tumor phenotype.
TILs and tumor cells display differential profiles of
cytokine production
We next examined the profile of cytokine production within TIL and
tumor populations. T cells were stimulated with mitogens prior to
assessment of IFN-g, IL-4, IL-10, and IL-17 expression. Interestingly,
substantial levels of cytokine production were observed from the
TIL and tumor populations, indicating that both subsets retain
some functional capacity.
Cytokine production from tumor cells was seen in almost all cases
(Figure 4A). Secretion of IL-17 and IL-4 was particularly increased
(P 5 .04, Wilcoxon), and the median percentage of tumor cells
producing IFN-g, IL-17, IL-4, and IL-10 was 8%, 21%, 11%, and
1%, respectively, although the range was wide.
Within nontumor CD41 cells, the most striking feature was
substantial IL-17 production within TILs and PBMCs. IFN-g and
IL-17 were also the predominant cytokines produced by CD81 TILs
(median, 46% and 48%, respectively), and IL-17 production within
CD81 PBMCs was substantially increased compared with control
PBMCs (median, 29% vs 6%), revealing a powerful influence of MF on
systemic cytokine production. tSNE plots revealed some heteroge-
neity of cytokine production within tumor and TIL subsets (Figure 4B).
The tumor cell phenotype diverges further from that of
TILs during disease progression
We next assessed how the phenotype of tumors and TILs was
related to disease stage or clinical progression. Clinical stage was
correlated initially to the expression of individual surface proteins
on all lymphoid populations (tumors, TILs, and PBMCs), but no
correlations were observed after multiple testing correction. The 3
major phenotypic subsets of MF also were not related to clinical
stage or degree of TIL infiltrate. A decrease in LAG-3 on CD4 and
CD8 PBMCs (P 5 .027 and P 5 .016, Wilcoxon) was seen in
relation to increasing stage.
However, because MF tumor phenotype had been observed to
diverge markedly from that of TILs, we also investigated whether this
dissimilarity was related to disease activity. As such, the Euclidean
distance between tumor phenotype and CD4 TIL was determined
for each sample and related to clinical factors.
As anticipated, the phenotype of individual CD41 and CD81 TIL
populations was very similar to that of the mean CD41 TILs,
whereas tumor populations exhibited a significant divergence
(Figure 5A). However, a markedly higher deviation from consensus
TIL phenotype was apparent in advanced disease (tumor vs patch
and plaque, P 5 .022, Figure 5B). As such, the phenotype of the
tumor most closely resembles that of TILs in early-stage disease but
diverges away from this during disease progression.
Disease progression is also associated with reduced
functional activity within TIL populations
Finally, we contrasted cytokine production and cytotoxic activity
in early-stage (patch or plaque) or late-stage disease (tumor).
Cytokine production was decreased during disease progression,
and the most significant reduction was in relation to IL-17
production: 4.7- and 1.3-fold decreases in median expression were
observed within CD41 TIL and CD81 TIL populations, respectively
(Figure 5E). A small decrease in IL-10 production was also seen in
CD41 TILs in late-stage disease (P 5 .047, Wilcoxon). CD107a
expression was observed on 17% and 19% of CD41 and CD81
T cells, respectively, in early-stage disease, but this decreased
markedly to 2% and 4% of cells within late-stage tumors
(Figure 5C-D).
Discussion
The treatment of advanced MF remains poor, and immunotherapy
may offer new opportunities.13,14 The introduction of checkpoint
inhibitors is showing some promise, with objective and stable
responses in 38% of patients in a recent report.11 As such, it
is now important to understand the biological basis for the
heterogeneity of disease response and identify opportunities for
appropriate targeting of immunotherapy.9
TILs are correlated with clinical outcome in many tumors,15 and we
were able to use TCRBV-specific staining to discriminate between
TILs and tumor cells and contrast their phenotypic and functional
features in early- and late-stage disease.16,17
The most striking feature of TILs was expression of a range of
inhibitory checkpoint receptors in a profile typical of the “exhaus-
tion” documented in other cancer settings. The profile was very
similar between CD41 and CD81 populations and was character-
ized by coexpression of PD-1 and TIGIT. PD-1 expression is
induced by chronic TCR engagement; it is likely that this reflects
antigenic recognition of tumor cells, although we did not examine
functional interactions within this study. Of note, the TIL phenotype
was found to be strikingly homogeneous between patients and
within individual patients at different stages of disease. This shows
that the tumor-specific immune response is constrained in its
degree of plasticity during disease progression.
In contrast, the phenotype of the MF tumor cell clustered into
3 distinct groups that were characterized by variable levels of
HLA-DR expression: high, medium, and low. We term these groups
as “cold” (HLA-DR2), “exhausted” (HLA-DR1 and PD-11), and
“evasive” (HLA-DR11 and PD-L11). The “exhausted” subgroup
was the most common and expressed high levels of PD-1, which
must again reflect continued physiological TCR engagement or
aberrant intracellular signaling. Nguyen et al18 also demonstrated
PD-1 expression in .60% of cases of MF and showed this to
be useful in the differential diagnosis from PD-12 tumors, such as
cutaneous lymphoid dyscrasia or primary cutaneous anaplastic
large cell lymphoma. High-level PD-1 expression on CD41 T cells is
also not a feature of inflammatory skin diseases, such as psoriasis.19
If PD-1 expression does indeed reflect chronic physiological TCR
engagement, this suggests that local autoantigen recognition may
play a role in development of disease.20 High levels of HLA-DR are
observed on keratinocytes in MF and indicate the potential for
peptide presentation to CD41 T cells.21,22 In addition, it is possible
that MF tumor cells recognize peptide targets on other tumor
cells or TILs; functional studies will be required to address this
question. Finally, it must also be considered that PD-1 expression
may represent a response to aberrant TCR-associated signaling
resulting from tumor-associated somatic mutations.23 Assessment
of PD-1 expression on tumors may act as an important determinant
of outcome, although interpretation of immunohistochemical and
26 FEBRUARY 2019 x VOLUME 3, NUMBER 4 IMMUNOPHENOTYPIC PROFILE OF MYCOSIS FUNGOIDES 525
.For personal use onlyon February 26, 2019. by guest  www.bloodadvances.orgFrom 
Fr
ac
tio
n 
of
 IF
N-
ga
m
m
a 
pr
od
uc
ing
 c
ell
s
CD8 IFN-gamma Production
HD CD8
n=9
0.0
0.5
1.0
n=19 n=19
PB CD8 TIL CD8
PopulationPopulation
Fr
ac
tio
n 
of
 IL
4 
pr
od
uc
ing
 c
ell
s
CD4 IL4 Production
HD CD4 PB CD4 TIL CD4 Tumor
n=9 n=11 n=11 n=11
0.0
0.5
1.0
*
Fr
ac
tio
n 
of
 IL
10
 p
ro
du
cin
g 
ce
lls
CD4 IL10 Production
HD CD4
0.0
0.5
1.0
PB CD4 TIL CD4
Population
n=9 n=11 n=11 n=11
Tumor
*
Fr
ac
tio
n 
of
 IL
17
a 
pr
od
uc
ing
 c
ell
s
CD8 IL17a Production
HD CD8 PB CD8 TIL CD8
n=9 n=20 n=20
****
**
****
0.0
0.5
1.0
Population
HD CD4
0.0
0.5
Fr
ac
tio
n 
of
 IL
 17
a 
pr
od
uc
ing
 c
ell
s
1.0
CD4 IL17a Production
PB CD4 TIL CD4
Population
Tumor
n=9 n=11 n=11 n=11
**
***
***
**
Fr
ac
tio
n 
of
 IF
N-
ga
m
m
a 
pr
od
uc
ing
 c
ell
s
0.0
0.5
1.0
CD4 IFN-gamma Production
HD CD4 PB CD4 TIL CD4
Population
Tumor
n=9 n=11 n=11 n=11
Population
HD CD4
PB CD4
TIL CD4
Tumor
Population
HD CD4
PB CD4
TIL CD4
Population
HD CD8
PB CD8
TIL CD8
Population
HD CD8
PB CD8
TIL CD8
Tumor
Population
HD CD4
PB CD4
TIL CD4
Tumor
Population
HD CD4
PB CD4
TIL CD4
Tumor
A
TCR CD4 CD8 Multiplex
IFN-gamma
IFN-gamma
CD8 TIL IL17a producing CD8
Th2 CD4 TIL
TReg CD4 TIL
Th1 CD4 TIL
Th17 CD4 TIL
IL17A IL4
CD8 TIL
CD4 TIL
IL10
tumor
B
Figure 4. Cytokine production. (A) Cytokine production in the T cell subsets. Production of IL-17 was high in the microenvironment in tumors and TILs. IL-4 production
was elevated only in the tumor population. Tumor and TILs were capable of producing IFN-g. IL-10 production occurred in a handful of tumor cases, but the median IL-10
production was highest in the CD4 TIL population. (B) tSNE clustering of cytokine data, which shows the T helper cell subsets of the immune response. This tumor was a
producer of IL-17 and IL-4. *P , .05; **P , .01; ***P , .001; ****P , .0001.
526 MURRAY et al 26 FEBRUARY 2019 x VOLUME 3, NUMBER 4
.For personal use onlyon February 26, 2019. by guest  www.bloodadvances.orgFrom 
0TIL CD4
n=19 n=19 n=19
1
2
3
4
TIL CD8
Kruskal-Wallis, p = 5.5e-06
Population
Eu
cli
de
an
 d
ist
an
ce
 o
f p
op
ula
tio
n
fro
m
 m
ea
n 
CD
4 
TI
Ls
Tumor
A
1
Early
n=13 n=6
2
3
4
Wilcoxon, p = 0.02
Clinical disease stage of biopsy
Eu
cli
de
an
 d
ist
an
ce
 o
f t
um
or
 p
op
ula
tio
n
fro
m
 p
air
ed
 C
D4
 T
IL
Late
B
n=10 n=10 n=10 n=7
Tissue
0
PB
25
50
75
100 Wilcoxon,
p = 0.021
CD4 CD8
Wilcoxon,
p = 0.045
CD
10
7a
 su
rfa
ce
 e
xp
re
ss
ion
 (%
)
TIL PB TIL
C
n=4 n=6 n=3 n=4
Clinical disease stage of biopsy
0
Early
25
50
75
100 Wilcoxon,
p = 0.043
CD4 CD8
Wilcoxon,
p = 0.11
CD
10
7a
 su
rfa
ce
 e
xp
re
ss
ion
 in
 T
IL
s (
%
)
Late Early Late
D
0.00
0.25
0.50
0.075
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.00
0.25
0.50
0.75
p = 0.64 p = 0.03 p = 0.51 p = 0.16
n=7
p = 0.4
p = 0.29 p = 0.096 p = 0.32 p = 0.19
Early Late Early Late Early Late Early Late
p = 0.03 p = 0.51 p = 0.047
Population
Tumor
TIL CD4
TIL CD8
n=7
n=7n=12 n=7n=13 n=7n=13 n=7
TIL C
D
8
TIL C
D
4
Tum
or
n=12
n=4 n=7 n=4 n=7 n=4 n=7 n=4
n=4 n=7 n=4
il17a il4 il10ifng
n=7 n=4 n=7 n=4
1.00
Fr
ac
tio
n 
cy
to
kin
e 
pr
od
uc
ing
Sample type
E
Figure 5. Phenotypic and functional changes with clinical stage. (A) Euclidean distance between the “average CD41 TIL phenotype” and that of individual CD41 TIL,
CD81 TIL, and MF tumor phenotypes. This demonstrates that the MF tumor phenotype diverges markedly from that of the TIL populations. (B) Euclidean distance between the CD41 TIL
phenotype and that of the MF tumor phenotype in relation to the clinical stage of the disease. Early-stage disease was defined as patch and plaque, whereas late-stage disease included
26 FEBRUARY 2019 x VOLUME 3, NUMBER 4 IMMUNOPHENOTYPIC PROFILE OF MYCOSIS FUNGOIDES 527
.For personal use onlyon February 26, 2019. by guest  www.bloodadvances.orgFrom 
fluorescence-activated cell sorting–based assays can be
challenging.24,25 In contrast to relatively high levels of PD-1
expression, PD-L1 was increased on only 35% of tumors and was
observed in association with high HLA-DR. As such, our data, in
contrast to some degree with other reports,8 suggest that the role
of PD-L1 in MF tumor evasion may be less salient than in many other
tumors. Fas and FasL also appear to be important regulators of
clinical progression, and high levels were observed on TILs,
although they were downregulated on CD41 PBMCs26 during
disease progression.27 Fas expression in MF is often associated
with high levels of FLICE inhibitory protein28 and emphasizes that
future work will be required to assess the relationship between
somatic mutation and surface phenotype.29 These observations
suggest that T cells are undergoing considerable proliferation within
MF lesions, and high levels of Ki67 expression are indeed observed
in cells within the epidermis, although not in dermal populations.30
The relative expression of HLA-DR was the major discriminating
factor in relation to tumor phenotype. This might reflect recent TCR
engagement,30 although HLA-DR is also expressed aberrantly on
many tumors and correlates with PD-L1 expression and response to
checkpoint blockade.31 The physiological role of HLA-DR expres-
sion in relation to immune surveillance is uncertain, because it may
present peptide to tumor-specific CD41 effector cells and Tregs.
HLA-DR engagement can also instigate biochemical pathways that
may directly favor tumor growth32; therefore, its role may go beyond
antigen presentation. Of note, high-level HLA-DR expression on MF
tumors did correlate with PD-L1 expression, but no differences
were observed in the relative proportion of Tregs in this subgroup.
The measurement of cytokine production by tumors and TILs
revealed a range of novel observations. Perhaps most significant
was the finding that both groups were not functionally exhausted
but retained high-level expression of cytokines. These cytokines
could represent novel targets for therapy, and a common feature,
which paralleled membrane phenotype, was that the pattern of
production by TILs was largely homogeneous, whereas that of
tumor cells exhibited considerable diversity. CD41 and CD81 TILs
expressed a predominant pattern of IFN-g and/or IL-17 production,
seen in ;25% and 50% of cells, respectively. Expression of IL-17
Figure 5. (continued) only the tumor subtype. The MF phenotype is seen to diverge most markedly from that of the TIL populations in biopsies from patients with late-stage disease.
(C) CD107a surface expression is higher in TILs compared with matched blood, suggesting recent microenvironment degranulation. (D) CD107a surface expression is lower with
increasing clinical stage. (E) Cytokine production by stage, demonstrating a general trend for decreased cytokine production in later stages, significant in IL-17 and IL-10 in CD4 TILs.
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might represent selection for cells with potent tumor-specific activity
or could simply reflect its role in cutaneous immune responses.33
Production of IL-4 and IL-10 was very low within the TIL groups. In
contrast, tumors expressed high levels of cytokines, most notably IL-4
and IL-17, although the pattern varied markedly in different patients.
The production of IL-4 supports previous reports showing a T helper
2 cell bias in MF and a direct role for IL-4 in suppression of T helper
1 cell cytokine production from TIL populations.16 IL-17 was also
highly expressed by many tumors, as previously reported.34,35
Interestingly, the IFN-g/IL-17 ratio within CD41 and CD81 PBMCs
was 12.4 and 9.7, respectively, in healthy donors but fell to only 1.35
and 1.46 in patients. This systemic influence of MF has been
observed previously and exemplifies how a localized cutaneous lesion
can markedly influence cytokine production within the peripheral
lymphoid repertoire.34,36
As previously reported, the expression of IL-17 decreased during
disease progression.34 IL-23 is themajor regulator of IL-17 production,
and high levels of IL-23 are present within epidermal keratinocytes
and dermal lymphocytes in patients with MF. Interestingly, expression
is lower in patients with advanced disease and may explain the
associated reduction in IL-17.37 Therefore, IL-17–IL-17R axis may
represent a potential target for MF treatment, particularly in earlier-
stage disease. Antibody-mediated blockade of IL-17 is highly effective
in the treatment of psoriasis but has not, to our knowledge, been used
in patients with MF.
The divergence of the tumor cell phenotype away from TILs
increased during disease progression and would suggest that
TILs act to control localized disease, but stochastic acquisition
of genetic and epigenetic changes within the MF tumor lead to
tumor evasion (Figure 6). This was confirmed by a decrease in
degranulation and cytokine production by TILs in late-stage disease.
Importantly, our study shows that tumor escape may occur along 3
major phenotypic pathways discriminated by the relative expres-
sion of HLA-DR.23 Given the significant heterogeneity of MF and the
relatively limited sample size in our study, it will now be important
that these observations are repeated on a confirmatory dataset.
Our findings uncover the complex phenotypic and functional
relationships within tumor and TIL subpopulations in MF. These
are likely to influence the efficacy of immunotherapy and may
provide an explanation for the heterogeneous responses reported
with immune checkpoint therapy. Therefore, characterization of the
immune microenvironment may come to represent an important tool
to guide personalized clinical management.
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